Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy for advanced third-line or later thoracic malignant solid tumors
ChiCTR1800019211Phase 4Recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in bronchial carcinoma, esophageal cancer, thymic carcinoma (TC) and 1 more, sponsored by Army Specialized Medical Center. Primary endpoint: progression-free survival. Started Nov 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
bronchial carcinomaesophageal cancerthymic carcinoma (TC)No single canonical name exists, as this is an umbrella term. Common canonical diseases in this group include "non-small cell lung cancer", "small cell lung cancer", "thymoma", etc.
Beyond the preview
Go deeper on ChiCTR1800019211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019211.